Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
Earnings Data
Report Date
Apr 23, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.47Last Year’s EPS
0.32Same Quarter Last Year
Strong Buy
Based on 21 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational recovery, solid revenue and margin improvement, robust cash generation, and several product and commercialization catalysts (G7 15-day, Smart Basal, Stelo, EHR integration). Management acknowledged prior supply/sensor deployment issues but demonstrated clear remediation and sequential margin recovery. Near-term headwinds include ramp-related OpEx for the Ireland facility, Q1 cadence seasonality, and uncertainty around CMS timing and competitive/payer dynamics, but these are framed as manageable or temporary. Overall the positives (growth, margin expansion, cash, product momentum) materially outweigh the headwinds.Company Guidance
Revenue Growth (FY2025 & Q4)
Worldwide revenue of $1,260,000,000 in FY2025 vs $1,110,000,000 in 2024, representing reported growth of 13% (12% organic). Q4 US revenue $892,000,000 (+11% YoY); international revenue $368,000,000 (+18% YoY; +15% organic).
Gross Margin Expansion and Operational Recovery
Q4 gross profit $799.8M representing 63.5% of revenue vs 59.4% in prior year (up ~410 bps YoY). Management drove >200 bps of sequential gross-margin improvement in Q4 through rebuilt inventory, reestablished ocean freight, and improved scrap rates.
Profitability and Cash Generation
Q4 operating income $331.5M (26.3% of revenue) and adjusted EBITDA $422.2M (33.5% of revenue) vs 27% last year. Net income $265.1M ($0.68 per share). Company closed the quarter with ~$2.0B cash and cash equivalents and surpassed $1.0B of free cash flow in 2025 for the first time.
Product Innovation & G7 15-day Rollout
Broad US rollout of DexCom G7 15-day system (available across all channels as of early January) with strong early feedback on longer wear time and improved accuracy; management states this is the most accurate sensor they have produced and expects G7 15-day to contribute to margin expansion over time.
New Product Features & Clinical Initiatives
Smart Basal early-access launch beginning this month (aimed at type 2 patients on basal insulin); DexCom Direct EHR integration onboarding at >160 health systems; Stelo updates including a comprehensive nutrition database and redesigned app planned; clearance received for new patch technology expected to improve sensor survival.
International Momentum
International organic revenue growth of 15% in Q4 with notable strength in Germany, UK and France (France among fastest-growing markets due to type 2 access expansion); management targets further international expansion and plans additional product introductions for non-US markets.
Capital Allocation Actions
Settled $1.2B of expiring convertible notes in cash and repurchased $300M of stock in the open market during Q4 while maintaining a strong ~$2.0B cash position.
Stelo (Consumer Wellness) Contribution
Stelo delivered ~$130M of revenue in 2025 (contributed at the top end of the 2–3% growth contribution previously referenced) and is expected to contribute roughly one percentage point to 2026 growth; management views Stelo as both consumer product and a funnel for covered CGM as access expands.
2026 Financial Guidance
Guidance for 2026 revenue $5.16B–$5.25B (growth 11%–13%). Non-GAAP full-year gross margin expected 63%–64%; non-GAAP operating margin ~22%–23%; adjusted EBITDA margin ~30%–31%. Company expects gross margin expansion of 200–300 bps in 2026 driven by lower freight, manufacturing efficiencies and G7 15-day.
DXCM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DXCM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 12, 2026 | $65.08 | $70.02 | +7.59% |
Oct 30, 2025 | $68.20 | $58.22 | -14.63% |
Jul 30, 2025 | $89.06 | $80.77 | -9.31% |
May 01, 2025 | $70.26 | $81.62 | +16.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Dexcom (DXCM) report earnings?
Dexcom (DXCM) is schdueled to report earning on Apr 23, 2026, After Close (Confirmed).
What is Dexcom (DXCM) earnings time?
Dexcom (DXCM) earnings time is at Apr 23, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DXCM EPS forecast?
DXCM EPS forecast for the fiscal quarter 2026 (Q1) is 0.47.
